|
|
|
|
||
Question from a non scientistHow similar or dissimilar is recurrent respiratory papillomatosis (RRP) to pulmonary arterial hypertension (PAH)? I own XLRN and recently it went ballistic. Over the weekend Bloomberg reported that it will be bought out for $11B. XLRN might be a COVID play if sotatercept is effective in PAH patients (which phase 2 trial has already shown). Was wondering if Precigen could venture into PAH if it is not to dissimilar to RRP. |
return to message board, top of board |